bi 705564
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2017 (NCT03123185)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 705564
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03747926 | Phase 1 | Apr 5, 2019 | Boehringer Ingelheim |
| NCT03771885 | Phase 1 | Mar 16, 2019 | Boehringer Ingelheim |
| NCT03325712 | Phase 1 | Nov 17, 2017 | Boehringer Ingelheim |
| NCT03123185 | Phase 1 | Apr 27, 2017 | Boehringer Ingelheim |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 4 | 4 | 1 | 2017 |
1 organizations
Page 1 / 1